Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization.
about
Coexpression of human somatostatin receptor-2 (SSTR2) and SSTR3 modulates antiproliferative signaling and apoptosisAcromegaly pathogenesis and treatmentFunctional characterization of G-protein-coupled receptors: a bioinformatics approach.Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin.Exploring a role for heteromerization in GPCR signalling specificity.Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1--molecular pathways.Homologous and heterologous in vitro regulation of pituitary receptors for somatostatin, growth hormone (GH)-releasing hormone, and ghrelin in a nonhuman primate (Papio anubis).Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2.Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5.Differential somatostatin receptor (SSTR) 1-5 expression and downstream effectors in histologic subtypes of growth hormone pituitary tumorsPeptide receptor targeting in cancer: the somatostatin paradigm.Use of the metallothionein promoter-human growth hormone-releasing hormone (GHRH) mouse to identify regulatory pathways that suppress pituitary somatotrope hyperplasia and adenoma formation due to GHRH-receptor hyperactivation.δ-opioid receptor and somatostatin receptor-4 heterodimerization: possible implications in modulation of pain associated signaling.Molecular signatures of mu opioid receptor and somatostatin receptor 2 in pancreatic cancer.The somatostatin receptor subtype 5 in neuroendocrine tumours.Pasireotide for the treatment of Cushing's disease.Cross-talk and modulation of signaling between somatostatin and growth factor receptors.Octreotide long-acting repeatable for acromegaly.Pathophysiology of GPCR Homo- and Heterodimerization: Special Emphasis on Somatostatin ReceptorsHeterodimerization of β2 adrenergic receptor and somatostatin receptor 5: Implications in modulation of signaling pathway.AIP inactivation leads to pituitary tumorigenesis through defective Gαi-cAMP signaling.Somatostatin receptor ligands in the treatment of acromegaly.The predicted ensemble of low-energy conformations of human somatostatin receptor subtype 5 and the binding of antagonists.Somatostatin and somatostatin analogues reduce PDGF-induced endometrial cell proliferation and motility.Differential efficacy of SSTR1, -2, and -5 agonists in the inhibition of C6 glioma growth in nude mice.Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects.Simultaneous method for analyzing dimerization and signaling of G-protein-coupled receptor in yeast by dual-color reporter system.Balance between somatostatin and D2 receptor expression drives TSH-secreting adenoma response to somatostatin analogues and dopastatins.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New NomenclatureNew directions in pharmacological treatment of acromegaly
P2860
Q24337066-923FA37F-843E-4C22-8046-D7BEC87D2B30Q24647360-28781C2B-FA96-4D87-A172-ABBAAA5B7BF0Q30009384-2A8DFA46-4882-4CF7-9EEA-7B7A8BD1D6D6Q33801805-52CECEB3-5701-48F0-9F46-64DEB64E2BC5Q34660378-606BF562-4FF0-4319-A167-CBA4864A8EF1Q35216414-0A1CD7CD-352C-477A-84E7-F6C042EF2573Q35646087-C469E15B-F567-4F0C-A97F-D61907FBB7B7Q35986032-2AC51F95-4AAD-4500-BA50-27C2BE7970D1Q36065515-249A52B6-7775-4332-B01B-06B34A96E653Q36270932-E7381013-A09E-46C9-AD68-D54FF5001E81Q36638046-6E50B622-4CB7-4EA3-A779-F789A844FA5CQ37244671-C711C775-54D8-451F-84B0-13A1F77000C4Q37453223-47294A60-B042-4675-B5F3-017326D1A1A5Q37573308-BBF3C59A-3AB9-4564-96D0-15448DB6AADAQ37691450-0123CC48-C987-4351-BE89-ADC24C6DC241Q37763714-ACA3B08A-E709-451F-8743-A4BBAABF34EDQ37922648-9441E50A-13F8-4046-A144-BC056704EB94Q37990556-B8A907C9-B9BB-44A1-BB35-1CA14F4DACE9Q38166623-561E1B2D-64AF-4873-AEB7-C854F1C4F304Q38304895-726DCD56-AEE3-4166-BC52-98BC022A9CB3Q39012320-30457362-C37B-48EC-BCA6-EBE9A0E0579CQ39125449-FE6AC3E1-3E6C-46CA-9238-55D71255EE55Q41219614-C9A898E0-9C64-4A08-BBD6-BA150A6B2AF0Q42506433-BF92FDB8-0CD4-4493-A696-7E676C4B5B0CQ48476082-97A5CB59-897F-48DE-81B1-BDC02E2CBF11Q50079728-9052CC69-AB67-47DC-9625-15F196B0758DQ50470951-71130829-B241-40C7-95A5-EF932DE9452CQ54353594-874583EF-E251-4EAE-9DF0-40B2AECFAA10Q57144951-70C604EE-69DE-4360-AB88-CBEFE9CB40F5Q58897890-11A3764C-E954-411D-9104-5741DD282BBC
P2860
Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Cell growth inhibition and fun ...... y receptor heterodimerization.
@en
Cell growth inhibition and fun ...... y receptor heterodimerization.
@nl
type
label
Cell growth inhibition and fun ...... y receptor heterodimerization.
@en
Cell growth inhibition and fun ...... y receptor heterodimerization.
@nl
prefLabel
Cell growth inhibition and fun ...... y receptor heterodimerization.
@en
Cell growth inhibition and fun ...... y receptor heterodimerization.
@nl
P2093
P2860
P356
P1476
Cell growth inhibition and fun ...... by receptor heterodimerization
@en
P2093
Brian Collier
Haydar Alturaihi
Philippe Jaquet
Ujendra Kumar
P2860
P304
P356
10.1210/ME.2007-0334
P577
2008-07-24T00:00:00Z